Opendata, web and dolomites

DMD2CURE

Correction of duplications in the DMD gene by a CRISPR/Cas9 approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DMD2CURE project word cloud

Explore the words cloud of the DMD2CURE project. It provides you a very rough idea of what is the project "DMD2CURE" about.

linked    therapeutic    muscular    feasible    duplication    despite    500    delayed    exist    leiden    tandem    milestones    necrosis    almost    tools    technologies    mutation    recessive    removing    frame    arena    10    male    skipping    muscle    pathologies    contiguous    strategy    nucleases    uses    termination    crispr    fibrosis    skeletal    chose    coding    grna    repair    promises    dmd    reported    therapies    model    gene    cas9    limited    editing    duplications    occurs    employ    deletions    births    protein    synthetic       shift    revolutionizing    followed    disorder    frequent    introduce    applicable    sequences    deletion    expression    therapy    restoring    regions    intronic    alterations    sequence    translation    represented    inversion    cardiac       weakening    exon    premises    date    disease    dystrophy    molecular    treatment    genome    generally    database    exonic    premature    identical    mutations    respiratory    induce    duchenne    progressive    hold    live    diseases    dystrophin    pave    wasting    deleted    sites    incidence    motor   

Project "DMD2CURE" data sheet

The following table provides information about the project.

Coordinator
ASSOCIATION GENETHON 

Organization address
address: RUE DE L INTERNATIONALE 1 BIS
city: EVRY
postcode: 91002
website: www.genethon.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.genethon.fr/en/
 Total cost 185˙076 €
 EC max contribution 185˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASSOCIATION GENETHON FR (EVRY) coordinator 185˙076.00

Map

 Project objective

Duchenne muscular dystrophy is an X-linked recessive muscle-wasting disease, characterized by progressive weakening of skeletal, respiratory, and cardiac muscle followed by necrosis and fibrosis. DMD affects ~1:3,500 live male births and is associated with delayed motor milestones. DMD occurs as a result of mutations within the DMD gene that lead to premature termination of translation. The most frequent type of mutations are exonic deletions and duplications that induce a frame-shift in the protein-coding sequence. To date no effective treatment exist for this disorder. Duplications account for ~5–10% of all reported mutations in DMD in the Leiden database, although the incidence may be higher. Despite the limited number in DMD, duplications are widespread in almost all diseases and are generally neglected by therapeutic approaches. New molecular tools, now represented by genome-editing technologies that use synthetic nucleases in order to introduce targeted alterations at specific sites in the genome, hold great promises for revolutionizing the gene therapy arena. According to these premises, we propose a novel strategy based on the CRISPR/Cas9 system to repair tandem duplications by removing the mutation: compared to the exon deletions approach which uses two gRNA targeting two unique regions defining the sequence to be deleted, our approach will employ only one gRNA against a unique intronic sequence within the tandem duplication. This strategy will exploit the characteristic of tandem duplication (two identical contiguous sequences) and will result in the deletion or inversion of the mutation restoring the dystrophin expression. As a model we chose the exon 2 duplication which is the most frequent one in the DMD gene, but the same approach would be applicable to all tandem duplications. This study will pave the way for the development of therapies against duplications also in pathologies in which the exon skipping approach is not feasible.

 Publications

year authors and title journal last update
List of publications.
2017 Annalisa Lattanzi, Stephanie Duguez, Arianna Moiani, Araksya Izmiryan, Elena Barbon, Samia Martin, Kamel Mamchaoui, Vincent Mouly, Francesco Bernardi, Fulvio Mavilio, Matteo Bovolenta
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
published pages: 11-19, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.02.004
Molecular Therapy - Nucleic Acids 7 2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DMD2CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DMD2CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More